美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

美國抗疫概念

1,341.13

-8.1082-0.60%

漲家數：7

跌家數：13

平家數：- -

市盈率：- -

高：1,349.81

開：1,349.81

低：1,326.47

收：1,349.23

資料載入中...

阿斯利康宣佈最新架構和人事變動

阿斯利康中國架構大調整，高管變動引關注

生物科技馆

K藥皮下劑型陷專利糾紛，羅氏再砍3條管線，阿斯利康聯手3家本土藥企

医药经济报

輝瑞4月25日成交額為8.20億美元

莫德納4月25日成交額為2.11億美元

吉利德科學4月25日成交額為14.63億美元

阿斯利康4月25日成交額為4.62億美元

美股抗疫概念股多數下跌，BioNTech跌超15%

每日经济新闻

勒布的 Third Point 公司增持創可貼製造商 Kenvue 的股份

勒布的 Third Point 公司增持創可貼製造商 Kenvue 的股份

BUZZ-Novavax 因報告 FDA 要求對 COVID 疫苗進行新試驗而下跌

據《華爾街日報》報導，美國 FDA 要求 Novavax 完成 COVID-19 延遲注射的新臨牀試驗

據《華爾街日報》報導，FDA要求諾瓦克斯公司完成COVID-19延遲注射的新臨牀試驗

諾瓦瓦克斯醫藥盤中異動股價大跌5.73%

Nanoviricides, Inc.盤中異動股價大漲5.19%報1.42美元

吉利德科學盤中異動早盤股價大跌3.41%

Equillium, Inc.盤中異動股價大跌5.96%

吉利德科學(GILD)第一季同比扭虧為盈至13.15億美元

輝瑞英立達獲批國內首個且唯一晚期腎癌一線靶免聯合治療

輝瑞：阿昔替尼獲批中國首個且唯一晚期腎癌一線靶免聯合治療

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK4568/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"美國抗疫概念","latestPrice":1341.1263,"timestamp":1745611199999,"preClose":1349.2345,"halted":0,"volume":105403296,"delay":0,"changeRate":-0.006009,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":-8.108154,"latestTime":"04-25 16:00:00 EDT","open":1349.8055,"high":1349.8055,"low":1326.4735,"amount":5679459236.570498,"amplitude":0.017293,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.624317,"peRate":21.905145,"turnoverRate":0.006797,"increases":7,"decrements":13,"flats":0,"marketCap":1107563323728.5,"floatMarketCap":1088066496974.5},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1349.8055,"amplitude":0.017293,"preClose":1349.2345,"low":1326.4735,"pbRate":"3.624317","latestPrice":1341.1263,"volume":105403296,"delay":0,"open":1349.8055,"prevYearClose":1274.8187,"prevWeekClose":1341.7848,"prevMonthClose":1427.887,"prevQuarterClose":1427.887,"fiveDayClose":1341.7848,"twentyDayClose":1413.7192,"sixtyDayClose":1349.6512,"secType":"PLATE","market":"US","turnoverRate":0.006797,"peRate":21.905145,"marketCap":1107563323728.5,"floatMarketCap":1088066496974.5,"timestamp":1745611199999,"nameCN":"美國抗疫概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":7,"down":13,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530141329","title":"阿斯利康宣佈最新架構和人事變動","url":"https://stock-news.laohu8.com/highlight/detail?id=2530141329","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530141329?lang=zh_tw&edition=fundamental","pubTime":"2025-04-26 12:23","pubTimestamp":1745641380,"startTime":"0","endTime":"0","summary":"阿斯利康中国宣布组织架构调整和人事变动，聚焦呼吸与自体免疫、疫苗及免疫疗法两大领域。新设两大事业部，并有多项人事任命和离职。此举与公司产品管线进展密切相关，计划至2030年在中国引入至少20款创新药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042615321894e37d19&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042615321894e37d19&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","AZN","LU2456880835.USD","LU2236285917.USD","BK4568","LU0889565916.HKD","LU0109394709.USD","BK4007","LU0320765992.SGD","LU2462157665.USD","LU2417539215.USD","BK4585","LU1829250122.USD"],"gpt_icon":0},{"id":"2530146694","title":"阿斯利康中國架構大調整，高管變動引關注","url":"https://stock-news.laohu8.com/highlight/detail?id=2530146694","media":"生物科技馆","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530146694?lang=zh_tw&edition=fundamental","pubTime":"2025-04-26 11:46","pubTimestamp":1745639184,"startTime":"0","endTime":"0","summary":"今日，阿斯利康中国掀起了一场备受瞩目的组织架构变革，此次调整堪称 2025 年规模最大的一次。目前已知，现任阿斯利康中国助理副总裁童沁杰将继续掌舵慢阻肺病业务部，不过 R&I 事业部负责人的最终人选尚未确定。三位高管离任消息公布与此同时，阿斯利康中国今日还宣布了三位高管离任的消息。去年 10 月，阿斯利康中国对 BBU 进行架构调整，多个业务部门进行合并，刘谦被任命为阿斯利康中国呼吸消化事业部总经理。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250426150645a467cffa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250426150645a467cffa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1829250122.USD","LU2417539215.USD","BK4585","LU0889565916.HKD","BK4568","BK4007","LU0320765992.SGD","LU2456880835.USD","AZN","BK4588","LU2236285917.USD","LU0109394709.USD","LU2462157665.USD"],"gpt_icon":0},{"id":"2530114058","title":"K藥皮下劑型陷專利糾紛，羅氏再砍3條管線，阿斯利康聯手3家本土藥企","url":"https://stock-news.laohu8.com/highlight/detail?id=2530114058","media":"医药经济报","labels":["corporation","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530114058?lang=zh_tw&edition=fundamental","pubTime":"2025-04-26 11:02","pubTimestamp":1745636535,"startTime":"0","endTime":"0","summary":"K药皮下剂型被诉专利侵权4月24日，美国生物技术公司Halozyme在新泽西州的美国地方法院对默沙东提起专利侵权诉讼。据悉，Halozyme的MDASE皮下递送技术利用人透明质酸酶实现药物的快速、大容量皮下注射。为此，Halozyme正在寻求损害赔偿和禁令救济，以阻止默沙东的侵权行为。在肺癌领域，阿斯利康积极推动研究创新疗法，已与6家本土药企达成合作，推进8项联合治疗研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250426112537a467a720&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250426112537a467a720&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1116320901.HKD","LU1037948897.HKD","SG9999001440.SGD","LU2461242641.AUD","LU1162221912.USD","IE00B1BXHZ80.USD","LU0265550946.USD","IE00BN8TJ469.HKD","SGXZ57979304.SGD","LU1093756168.USD","IE00BLSP4452.SGD","LU0965509101.SGD","LU2324357040.USD","IE00BJJMRZ35.SGD","SG9999015341.SGD","BK4533","SG9999015358.SGD","LU1066053197.SGD","LU2023250504.SGD","LU1941712264.USD","LU1989772923.USD","MRK","LU1699723380.USD","LU1035773651.USD","LU1069347547.HKD","LU0265550359.USD","LU0266013472.USD","LU1430594728.SGD","LU0320765489.SGD","LU1934455863.HKD","IE00BJT1NW94.SGD","LU2361044949.HKD","AZN","SG9999013999.USD","LU2456880835.USD","LU1989771016.USD","LU0861579265.USD","LU2468319806.SGD","LU1934455194.USD","IE000M9KFDE8.USD","LU2361045086.USD","IE00B4R5TH58.HKD","IE0002141913.USD","LU2023250843.SGD","BK4550","LU0320765992.SGD","LU0203345920.USD","LU2361044865.SGD","LU2089984988.USD","BK4568"],"gpt_icon":0},{"id":"2530772119","title":"輝瑞4月25日成交額為8.20億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530772119","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530772119?lang=zh_tw&edition=fundamental","pubTime":"2025-04-26 10:18","pubTimestamp":1745633897,"startTime":"0","endTime":"0","summary":"美东时间2025年4月25日，辉瑞成交额为8.20亿美元，成交额较昨日增加3.34%，当日成交量为3584.77万股。辉瑞于2025年4月25日涨0.61%，报22.92美元，该股过去5个交易日涨3.52%，年初至今跌12.18%，过去60日跌13.9%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-04-25|8.20亿|3.34%|3584.77万|#|2025-04-24|7.94亿|-30.67%|3500.96万|#|2025-04-23|11.45亿|41.51%|5078.10万|#|2025-04-22|8.09亿|14.76%|3605.26万|#|2025-04-21|7.05亿|-41.56%|3202.10万|辉瑞是全球最大的制药公司之一，年销售额接近500亿美元。辉瑞在全球销售这些产品，国际销售额占其总销售额的近50%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250426101825a46793a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250426101825a46793a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE000M9KFDE8.USD","BK4533","SG9999003800.SGD","BK4592","LU0289739699.SGD","BK4581","LU0225771236.USD","BK4599","LU1057294990.SGD","PFE","IE00BLSP4452.SGD","LU1894683348.USD","SG9999002232.USD","LU0234572021.USD","SG9999013999.USD","BK4568","LU1023059063.AUD","IE00BLSP4239.USD","LU1066051498.USD","LU0321505439.SGD","BK4007","SGXZ57979304.SGD","LU0321505868.SGD","LU0058720904.USD","IE0002270589.USD","LU1883839398.USD","LU0868494617.USD","SG9999002224.SGD","LU0306807586.USD","BK4588","LU1894683264.USD","LU1066053197.SGD","LU0170899867.USD","SG9999011175.SGD","LU0225284248.USD","IE00B19Z3581.USD","LU0122379950.USD","BK4534","LU0456855351.SGD","LU0306806265.USD","SG9999001176.SGD","LU0985481810.HKD","BK4585","IE00B19Z3B42.SGD","SG9999001176.USD","IE00BBT3K403.USD","BK4550"],"gpt_icon":1},{"id":"2530197281","title":"莫德納4月25日成交額為2.11億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530197281","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530197281?lang=zh_tw&edition=fundamental","pubTime":"2025-04-26 10:02","pubTimestamp":1745632934,"startTime":"0","endTime":"0","summary":"美东时间2025年4月25日，莫德纳成交额为2.11亿美元，成交额较昨日增加62.78%，当日成交量为771.91万股。莫德纳于2025年4月25日跌0.62%，报27.22美元，该股过去5个交易日涨10.11%，年初至今跌34.54%，过去60日跌33.15%。截至 2024年9月，莫德纳拥有处于临床试验中的40个mRNA开发候选物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250426100215a6c8d01f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250426100215a6c8d01f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4548","BK4568","BK4534","BK4533","BK4501","BK4532","BK4551","MRNA","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"2530119082","title":"吉利德科學4月25日成交額為14.63億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530119082","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530119082?lang=zh_tw&edition=fundamental","pubTime":"2025-04-26 09:34","pubTimestamp":1745631298,"startTime":"0","endTime":"0","summary":"美东时间2025年4月25日，吉利德科学成交额为14.63亿美元，成交额较昨日增加35.59%，当日成交量为1420.82万股。吉利德科学于2025年4月25日跌2.81%，报103.17美元，该股过去5个交易日跌1.31%，年初至今涨12.48%，过去60日涨8.69%。吉利德对Pharmasset的收购带来了丙型肝炎药物索磷布韦片的使用权，该药物也是仍为治疗标准的较新的联合方案的一部分。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250426093502a6c8c7b2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250426093502a6c8c7b2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4578","BK4583","LU1066053197.SGD","BK4588","BK4566","IE00BZ1G4Q59.USD","LU0289739699.SGD","LU1571399168.USD","IE0002270589.USD","LU2089984988.USD","BK4585","LU0109394709.USD","IE00B3T34201.USD","LU1585245621.USD","LU0234570918.USD","BK4550","LU0058720904.USD","LU2087621335.USD","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","GILD","LU1430594728.SGD","LU1066051498.USD","LU2468319806.SGD","BK4139","IE00BKVL7J92.USD","LU0320765992.SGD","BK4532","BK4568","LU1839511570.USD","IE00B19Z3581.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2530607113","title":"阿斯利康4月25日成交額為4.62億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530607113","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530607113?lang=zh_tw&edition=fundamental","pubTime":"2025-04-26 09:16","pubTimestamp":1745630209,"startTime":"0","endTime":"0","summary":"美东时间2025年4月25日，阿斯利康成交额为4.62亿美元，成交额较昨日增加94.02%，当日成交量为666.27万股。阿斯利康于2025年4月25日涨0.03%，报69.57美元，该股过去5个交易日涨2.93%，年初至今涨7.91%，过去60日涨0.53%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-04-25|4.62亿|94.02%|666.27万|#|2025-04-24|2.38亿|-38.92%|343.21万|#|2025-04-23|3.90亿|-1.09%|567.40万|#|2025-04-22|3.94亿|128.16%|580.70万|#|2025-04-21|1.73亿|-32.74%|257.30万|1999 年，瑞典阿斯特拉公司与英国捷利康集团合并，成立了阿斯利康公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250426091702a467845e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250426091702a467845e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0889565916.HKD","LU2462157665.USD","LU2417539215.USD","BK4568","LU0109394709.USD","BK4585","LU2236285917.USD","BK4007","LU2456880835.USD","AZN","LU0320765992.SGD","BK4588","LU1829250122.USD"],"gpt_icon":0},{"id":"2530868192","title":"美股抗疫概念股多數下跌，BioNTech跌超15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530868192","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530868192?lang=zh_tw&edition=fundamental","pubTime":"2025-04-26 06:55","pubTimestamp":1745621711,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月26日，美股抗疫概念股多数下跌，Moderna跌0.62%，吉利德科学跌超2%，诺瓦瓦克斯医药跌逾5%，BioNTech跌超15%，阿斯利康涨0.03%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504263389420366.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504263389420366.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0234570918.USD","LU0889565916.HKD","IE00BZ1G4Q59.USD","GILD","BK4568","LU1066053197.SGD","LU1585245621.USD","IE00B19Z3581.USD","LU2468319806.SGD","LU0058720904.USD","BK4547","IE00BKVL7J92.USD","LU1571399168.USD","IE00B19Z3B42.SGD","LU0320765992.SGD","BK4139","IE00B3T34201.USD","LU0109394709.USD","BK4583","LU1066051498.USD","LU2087621335.USD","BK4532","BK4550","IE0002270589.USD","BK4588","LU0289739699.SGD","BK4566","BK4578","LU2089984988.USD","BK4585","IE00B7SZLL34.SGD","IE00BSNM7G36.USD","LU1430594728.SGD","LU1839511570.USD"],"gpt_icon":0},{"id":"2530196258","title":"勒布的 Third Point 公司增持創可貼製造商 Kenvue 的股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2530196258","media":"路透中文","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530196258?lang=zh_tw&edition=fundamental","pubTime":"2025-04-26 06:09","pubTimestamp":1745618944,"startTime":"0","endTime":"0","summary":"勒布的 Third Point 公司增持创可贴制造商 Kenvue 的股份Svea Herbst-Bayliss路透纽约4月25日 - 熟悉内情的消息人士周五透露，亿万富翁投资者丹尼尔-勒布的对冲基金Third Point正在增持KenvueKVUE.N的股份，因为一些投资者正在推动这家消费保健品公司进行战略调整。目前还不能确定 Third Point 的投资规模有多大，也不能确定该对冲基金是否与 Kenvue 董事会或管理层进行了接触。Third Point 的一位代表拒绝发表评论。英国《金融时报》周五首次报导了 Third Point 持有 Kenvue 股份的消息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nL4T3R3245:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","LU0345770993.USD","BK4524","KVUE","LU0122379950.USD","LU1221951129.SGD","LU2347655156.SGD","LU2505996509.AUD","BK4559","IE00B19Z3581.USD","LU2430703251.USD","IE00BVYPNV92.GBP","BK4568","IE00B7SZLL34.SGD","LU0203347892.USD","LU0320765489.SGD","LU2430703095.HKD","LU0114720955.EUR","LU1244550221.USD","BK4507","IE00B2B36J28.USD","LU1032466523.USD","IE00BLSP4452.SGD","LU0310800379.SGD","BBWI","LU2602419157.SGD","BK4554","LU1718418525.SGD","LU0466842654.USD","LU1074936037.SGD","JNJ","LU1162221912.USD","LU1674673428.USD","LU1732799900.SGD","LU2129689514.USD","LU0070302665.USD","LU0795875169.SGD","LU1244550494.USD","SG9999001440.SGD","LU1261432733.SGD","SG9999015952.SGD","AAP","LU1032955483.USD","LU0058720904.USD","BK4183","IE00BJT1NW94.SGD","LU1196500208.SGD","IE00BFTCPJ56.SGD","LU1585245621.USD"],"gpt_icon":1},{"id":"2530196237","title":"勒布的 Third Point 公司增持創可貼製造商 Kenvue 的股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2530196237","media":"路透中文","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530196237?lang=zh_tw&edition=fundamental","pubTime":"2025-04-26 06:09","pubTimestamp":1745618944,"startTime":"0","endTime":"0","summary":"勒布的 Third Point 公司增持创可贴制造商 Kenvue 的股份Svea Herbst-Bayliss路透纽约4月25日 - 熟悉内情的消息人士周五透露，亿万富翁投资者丹尼尔-勒布的对冲基金Third Point正在增持KenvueKVUE.N的股份，因为一些投资者正在推动这家消费保健品公司进行战略调整。目前还不能确定 Third Point 的投资规模有多大，也不能确定该对冲基金是否与 Kenvue 董事会或管理层进行了接触。Third Point 的一位代表拒绝发表评论。英国《金融时报》周五首次报道了 Third Point 持有 Kenvue 股份的消息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nL4S3R3245:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","IE0002270589.USD","LU0466842654.USD","SG9999015952.SGD","LU0122379950.USD","LU1261432733.SGD","BK4507","LU1162221912.USD","IE00B2B36J28.USD","BK4559","LU1221951129.SGD","LU1718418525.SGD","LU2602419157.SGD","LU0320765489.SGD","LU0070302665.USD","IE00B7SZLL34.SGD","IE00BVYPNV92.GBP","LU1196500208.SGD","LU2347655156.SGD","LU1032955483.USD","LU0203347892.USD","LU0310800379.SGD","LU2505996509.AUD","IE00BLSP4452.SGD","LU1674673428.USD","LU0795875169.SGD","LU0345770993.USD","LU2430703251.USD","BK4524","AAP","BK4183","BBWI","KVUE","JNJ","IE00B19Z3581.USD","LU1585245621.USD","SG9999001440.SGD","LU1032466523.USD","LU0114720955.EUR","BK4554","IE00BJT1NW94.SGD","LU1244550221.USD","IE00BFTCPJ56.SGD","LU1244550494.USD","LU1732799900.SGD","LU2129689514.USD","LU1074936037.SGD","LU2430703095.HKD","LU0058720904.USD"],"gpt_icon":1},{"id":"2530629031","title":"BUZZ-Novavax 因報告 FDA 要求對 COVID 疫苗進行新試驗而下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2530629031","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530629031?lang=zh_tw&edition=fundamental","pubTime":"2025-04-26 03:46","pubTimestamp":1745610380,"startTime":"0","endTime":"0","summary":"4月25日 - ** 疫苗生产商 Novavax NVAX.O 的股价在下午的交易中下跌 6.6% 至 6.61 美元** 华尔街日报》援引熟悉内情的人士的话报导称，尽管此前COVID-19疫苗的有效率达到了90%，但美国食品和药物管理局仍要求Novavax为其COVID-19疫苗再进行一次临床试验。** 周三，NOVAX称，如果COVID-19疫苗获得全面批准，美国食品和药物管理局要求该公司提供更多数据， 。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nL4T3R31V1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4547","BK4588","BK4139","NVAX","BK4585"],"gpt_icon":1},{"id":"2530623691","title":"據《華爾街日報》報導，美國 FDA 要求 Novavax 完成 COVID-19 延遲注射的新臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2530623691","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530623691?lang=zh_tw&edition=fundamental","pubTime":"2025-04-26 03:40","pubTimestamp":1745610029,"startTime":"0","endTime":"0","summary":"更新版 4-据《华尔街日报》报导，美国 FDA 要求 Novavax 完成 COVID-19 延迟注射的新临床试验在第 4 和第 5 段中添加了 Novavax 公司的评论意见据《华尔街日报》报导，FDA 要求对 COVID-19 注射剂进行新的试验Novavax 股票收盘下跌近 6. 路透4月25日 - 据《华尔街日报》周五援引知情人士的话报导，在此前推迟批准COVID-19疫苗后，联邦监管机构要求Novavax NVAX.O完成一项额外的临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7884860a095da688d55e8f59fb0acbc9","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nL4T3R31UO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4588","BK4547","BK4568","NVAX"],"gpt_icon":1},{"id":"2530644271","title":"據《華爾街日報》報導，FDA要求諾瓦克斯公司完成COVID-19延遲注射的新臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2530644271","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530644271?lang=zh_tw&edition=fundamental","pubTime":"2025-04-26 03:30","pubTimestamp":1745609453,"startTime":"0","endTime":"0","summary":"据《华尔街日报》报导，FDA要求诺瓦克斯公司完成COVID-19延迟注射的新临床试验路透4月25日 - 据《华尔街日报》周五援引熟悉内情的人士的话报导，在此前推迟批准Covid-19疫苗后，联邦监管机构要求Novavax NVAX.O完成额外的临床试验。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nL4T3R31U8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4547","NVAX","BK4568","BK4585"],"gpt_icon":0},{"id":"2530164896","title":"諾瓦瓦克斯醫藥盤中異動 股價大跌5.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530164896","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530164896?lang=zh_tw&edition=fundamental","pubTime":"2025-04-26 03:20","pubTimestamp":1745608845,"startTime":"0","endTime":"0","summary":"北京时间2025年04月26日03时20分，诺瓦瓦克斯医药股票出现波动，股价大幅下挫5.73%。截至发稿，该股报6.67美元/股，成交量431.707万股，换手率2.68%，振幅6.42%。机构评级方面，在所有7家参与评级的机构中，57%的券商给予买入建议，29%的券商给予持有建议，14%的券商给予卖出建议。诺瓦瓦克斯医药股票所在的生物技术行业中，整体跌幅为0.11%。诺瓦瓦克斯医药公司简介：诺瓦瓦克斯医药公司是一家从事疫苗开发的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250426032045a6c86d26&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250426032045a6c86d26&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4588","BK4585","NVAX","BK4547","BK4568"],"gpt_icon":1},{"id":"2530702132","title":"Nanoviricides, Inc.盤中異動 股價大漲5.19%報1.42美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530702132","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530702132?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 22:19","pubTimestamp":1745590784,"startTime":"0","endTime":"0","summary":"北京时间2025年04月25日22时19分，Nanoviricides, Inc.股票出现异动，股价快速上涨5.19%。截至发稿，该股报1.42美元/股，成交量4.7281万股，换手率0.30%，振幅2.89%。Nanoviricides, Inc.股票所在的生物技术行业中，整体跌幅为0.55%。Nanoviricides, Inc.公司简介：Nanoviricides Inc是一家纳米生物制药公司，致力于发现、开发和商业化治疗剂，以推进对患有危及生命的病毒感染患者的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425221944aa2c7bb0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425221944aa2c7bb0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NNVC","BK4139","BK4568"],"gpt_icon":0},{"id":"2530139608","title":"吉利德科學盤中異動 早盤股價大跌3.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530139608","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530139608?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 21:31","pubTimestamp":1745587905,"startTime":"0","endTime":"0","summary":"北京时间2025年04月25日21时31分，吉利德科学股票出现波动，股价快速下挫3.41%。吉利德科学股票所在的制药行业中，整体跌幅为0.18%。消息层面，截至21时31分，《吉利德科学首季扭亏为盈维持年度业绩预测》资讯为影响吉利德科学的重要信息。该信息摘要如下：吉利德科学在2023年第一季度实现了扭亏为盈，营收达67亿美元，净利润为13.15亿美元，优于市场预期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425213145a6c81d0a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425213145a6c81d0a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B19Z3581.USD","IE00BKVL7J92.USD","IE00BSNM7G36.USD","BK4568","BK4578","LU0109394709.USD","LU2089984988.USD","LU0234570918.USD","LU1839511570.USD","LU2468319806.SGD","LU0889565916.HKD","BK4588","BK4550","LU0058720904.USD","LU0289739699.SGD","IE00B19Z3B42.SGD","LU2087621335.USD","BK4585","LU1066051498.USD","LU0320765992.SGD","LU1430594728.SGD","LU1066053197.SGD","BK4139","IE0002270589.USD","GILD","IE00B7SZLL34.SGD","LU1571399168.USD","BK4566","IE00B3T34201.USD","BK4532","IE00BZ1G4Q59.USD","LU1585245621.USD","BK4583"],"gpt_icon":0},{"id":"2530139775","title":"Equillium, Inc.盤中異動 股價大跌5.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530139775","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530139775?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 21:31","pubTimestamp":1745587896,"startTime":"0","endTime":"0","summary":"北京时间2025年04月25日21时31分，Equillium, Inc.股票出现异动，股价快速跳水5.96%。Equillium, Inc.股票所在的生物技术行业中，整体跌幅为0.32%。Equillium, Inc.公司简介：Equillium Inc是一家临床阶段的生物技术公司，致力于开发新的治疗方法，以治疗严重的自身免疫性和炎症性疾病，或免疫炎症性疾病，具有高度未满足的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425213136a6c81cfc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425213136a6c81cfc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","EQ","BK4568"],"gpt_icon":0},{"id":"2530990724","title":"吉利德科學(GILD)第一季同比扭虧為盈至13.15億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530990724","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530990724?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 18:15","pubTimestamp":1745576112,"startTime":"0","endTime":"0","summary":"金吾财讯 | 吉利德科学(GILD)公布首季财报，按年扭亏为盈，录季度纯利13.15亿美元，对上财年同季录亏损41.7亿美元，主要涉及研发减值24.3亿美元及收购正进行研发所涉开支41.31亿美元拖累。季度每股摊薄纯利1.04美元，经调整后为1.81美元，略高于市场预期的1.79美元。季度收入按年跌不足1%至66.67亿美元，市场预期为68亿美元。公司爱滋病药Biktarvy销售按年升7%至31.5亿美元，符合市场预期。肝病药销售按年升3%至7.58亿美元。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/YTEwMTc4Njg5ODk4OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/YTEwMTc4Njg5ODk4OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"287876","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BKVL7J92.USD","LU1066053197.SGD","LU1066051498.USD","BK4568","BK4566","IE00B3T34201.USD","IE00BSNM7G36.USD","LU2089984988.USD","LU0109394709.USD","IE00BZ1G4Q59.USD","BK4583","LU1839511570.USD","IE0002270589.USD","BK4532","BK4578","IE00B19Z3B42.SGD","LU1430594728.SGD","BK4588","IE00B7SZLL34.SGD","GILD","BK4585","LU0234570918.USD","LU0889565916.HKD","LU2468319806.SGD","LU2087621335.USD","LU1571399168.USD","LU0058720904.USD","LU0289739699.SGD","LU0320765992.SGD","LU1585245621.USD","BK4550","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2530905116","title":"輝瑞英立達 獲批國內首個且唯一晚期腎癌一線靶免聯合治療","url":"https://stock-news.laohu8.com/highlight/detail?id=2530905116","media":"21经济网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530905116?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 16:57","pubTimestamp":1745571434,"startTime":"0","endTime":"0","summary":"南方财经4月25日电，辉瑞公司今日宣布，其口服靶向药英立达?（Inlyta?，通用名：阿昔替尼片）于2025年4月22日获得国家药品监督管理局（NMPA）批准，联合特瑞普利单抗用于中高危的不可切除或转移性肾细胞癌（RCC）患者的一线治疗，这也是中国肾癌治疗领域首个且唯一获批的一线靶免联合治疗方案。（21世纪经济报道）","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425171322a6c7d0d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425171322a6c7d0d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4533","LU0985481810.HKD","LU1066053197.SGD","BK4588","IE00BLSP4452.SGD","LU0456855351.SGD","LU0321505439.SGD","LU0289739699.SGD","PFE","LU0868494617.USD","SG9999001176.USD","BK4599","LU1883839398.USD","IE0002270589.USD","LU0225771236.USD","IE000M9KFDE8.USD","LU1023059063.AUD","LU1894683264.USD","BK4585","LU0122379950.USD","BK4550","BK4581","LU0058720904.USD","LU0306806265.USD","LU0306807586.USD","SG9999001176.SGD","LU0321505868.SGD","IE00BBT3K403.USD","IE00B19Z3B42.SGD","IE00BLSP4239.USD","BK4534","SG9999003800.SGD","LU0234572021.USD","LU0170899867.USD","LU1894683348.USD","SG9999002224.SGD","LU1057294990.SGD","BK4592","LU1066051498.USD","BK4007","SG9999002232.USD","SG9999013999.USD","SGXZ57979304.SGD","BK4568","SG9999011175.SGD","LU0225284248.USD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2530970288","title":"輝瑞：阿昔替尼獲批中國首個且唯一晚期腎癌一線靶免聯合治療","url":"https://stock-news.laohu8.com/highlight/detail?id=2530970288","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530970288?lang=zh_tw&edition=fundamental","pubTime":"2025-04-25 16:55","pubTimestamp":1745571304,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["SG9999003800.SGD","SG9999001176.SGD","LU0225771236.USD","LU0058720904.USD","LU1023059063.AUD","BK4533","LU0985481810.HKD","PFE","SG9999002232.USD","SG9999002224.SGD","IE00B19Z3B42.SGD","LU0122379950.USD","BK4007","BK4550","BK4588","LU0321505868.SGD","LU0306807586.USD","IE00BBT3K403.USD","LU0321505439.SGD","LU0234572021.USD","SG9999001176.USD","BK4585","BK4592","BK4568","LU1066053197.SGD","LU1066051498.USD","IE00BLSP4452.SGD","IE00BLSP4239.USD","SGXZ57979304.SGD","SG9999013999.USD","LU0868494617.USD","LU1883839398.USD","LU1894683264.USD","BK4534","IE000M9KFDE8.USD","BK4581","LU0456855351.SGD","BK4599","SG9999011175.SGD","LU0170899867.USD","RCC","LU0289739699.SGD","IE00B19Z3581.USD","LU0225284248.USD","LU0306806265.USD","LU1057294990.SGD","IE0002270589.USD","LU1894683348.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":1,"totalSize":177,"code":"91000000","status":"200"}]}}